Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
72.00    2.00 (2.86%)
Bid:
71.00
Ask:
73.00
Spread: 2.00 (2.817%)
Market Cap: £327.68m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Interim Results

28 Jan 2005 16:48

Readybuy PLC28 January 2005 READYBUY PLC (the "Company") UNAUDITED INTERIM RESULTSFor the six months ended 31 October 2004 Chairman's Statement During the period under review, the Company has successfully secured several newlistings for its products with supermarkets. We have also started to produce ourproducts in reasonable volumes and now distribute to a number of customers bothon a regional and national basis. Certain lines have been listed on apromotional basis to build customer awareness. Results Turnover in the period under review was £139,000 producing a loss before tax of£138,000 and a loss per share of 0.8p As at 31 October 2004, the Group had net cash of approximately £51,000. Our monthly cash burn has been substantially reduced during this same period. Strategy We continue to pursue our stated strategy of developing a top quality range ofchilled ready meals both in the retail and food service sectors. We also intendto develop other products which will complement the existing portfolio. Staff As the business has grown, all our staff have worked extremely hard to meetcustomer requirements and I would like to thank them for all their efforts Prospects Since the half-year, we have been working on several new listings which have notyet been confirmed. Accordingly, the Directors believe that the results for thefull year will fall below market expectations. The board is currently reviewing its working capital requirements and may seekto raise additional equity to invest further in the business and to fund theGroup through to profitability. Colin DaviesNon Executive Chairman- READYBUY PLCGROUP PROFIT AND LOSS ACCOUNTfor the six months ended 31 October 2004 Unaudited Audited Unaudited 6 months Period Period to 29/04/03 to 29/04/03 to 31/10/2004 30/04/2004 31/10/2003 £'000 £'000 £'000 TurnoverContinuing operations 139 19 0 Operating lossContinuing operations (137) (343) (114) Loss on ordinary activities before interest (137) (343) (114) Net interest (1) 0 0 Loss before taxation (138) (343) (114) Taxation 0 45 0 Loss after taxation (138) (298) (114) Dividends 0 0 0 Retained loss (138) (298) (114) Loss per shareBasic and diluted (0.8p) (2.2p) (1.2p) Dividends per share 0 0 0 READYBUY PLCGROUP BALANCE SHEETat 31 October 2004 Unaudited Audited Unaudited 31/10/2004 30/04/2004 31/10/2003 £'000 £'000 £'000 Fixed assetsGoodwill 629 646 671Tangible assets 208 218 212 837 864 883 Current assetsStock 17 7 0Debtors 116 82 52Cash at bank 276 429 659 409 518 711 Creditors falling due within one year (334) (323) (328) Net current assets 75 195 383 Total assets less current liabilities 912 1,059 1,266 Creditors falling due after one year (16) (25) (46) 896 1,034 1,220Capital and reservesCalled up share capital 90 90 90Share premium account 1,242 1,242 1,244Profit and loss account (436) (298) (114) Equity shareholders' funds 896 1,034 1,220 READYBUY PLC GROUP CASHFLOW STATEMENT for the six months ended 31 October 2004 Unaudited Audited Unaudited 6 months Period Period to 29/04/03 29/04/03 to to 31/10/2004 30/04/2004 31/10/2003 £'000 £'000 £'000 Operating loss (137) (343) (114) Depreciation and amortisation 33 82 42 Movement in working capital (17) (146) (163) Net cash outflow from operating activities (121) (407) (235) Net cash outflow from capital expenditure and financial investment (6) (42) (12) Purchase of subsidiary undertaking expenses and flotation - (272) (270) expenses Overdraft, net of cash, acquired with subsidiary undertaking - (6) (6) Net cash outflow from acquisitions and disposals - (278) (276) Net cash outflow before use of liquid resources and financing (127) (727) (523) Repayment of term loans - (220) (220) Capital element of finance lease payments (25) (19) (8) Issue of ordinary share capital net of redemption - 1,169 1,169 Net cash (outflow)/inflow from financing (25) 930 941 (Decrease)/Increase in cash in the period (152) 203 418 Analysis of net funds Cash at bank and in hand 276 429 659 Overdraft (225) (226) (241) 51 203 418 Debt repayable by instalments: Due within one year (18) (34) (24) Due after more than one year (16) (25) (46) (34) (59) (70) 17 144 348READYBUY PLCINTERIM ACCOUNTSfor the six months ended 31 October 2004 Notes 1 The unaudited results for the six month period have been prepared on a basis consistent with the accounting policies disclosed in the Group's 2004 accounts and do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985 2 The figures for the period ended 30 April 2004 have been extracted from the statutory accounts which have been delivered to the Registrar of Companies and received an unqualified audit report. 3 The calculation of the loss per share for the period is based on the loss after taxation divided by the average number of ordinary shares in issue, being 17,994,010 (31 October 2003 9,295,367 and 30 April 2004 13,585,434). This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jun 20263:00 pmRNSBlock Listing - Application to AIM
1st Jun 20267:00 amRNSClinical data on AVA6000 in salivary gland cancers
29th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
29th May 20267:00 amRNSBoard Director Changes
19th May 20267:00 amRNSUnaudited Preliminary Full Year 2025 Results
13th May 20267:00 amRNSNotice of Preliminary Results and Presentation
13th May 20267:00 amRNSIssue of Equity and Total Voting Rights
6th May 20267:00 amRNSPre|CISION® payload release vs approved ADCs
28th Apr 20267:00 amRNSBlock Listing Six Monthly Return
21st Apr 20267:00 amRNSAvacta data AACR underline AVA6103 profile
14th Apr 202611:37 amRNS-RChristina Coughlin - In Vivo 2026 Rising Leader
9th Apr 20267:00 amRNSQ1 2026 Business Update
8th Apr 20267:00 amRNS-RAvacta Announces Science Day 2026
31st Mar 20267:00 amRNSFirst patient treated in Phase 1 trial of AVA6103
27th Mar 20267:00 amRNSResult of Oversubscribed Fundraise
26th Mar 20265:16 pmRNSProposed Fundraise to raise approximately £10m
26th Mar 20264:44 pmRNSIssue of Equity
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
24th Feb 20267:00 amRNSPreCISION payload delivery advantage over ADC
18th Feb 20267:00 amRNS-RAvacta to Participate in Conference March 2026
9th Feb 20267:00 amRNSAppointment of CSO
3rd Feb 20267:00 amRNSFaridoxorubicin Program Clinical Updates
21st Jan 20267:00 amRNSFDA Clearance of IND Application for AVA6103
20th Jan 20267:01 amRNSYear-end trading update
20th Jan 20267:00 amRNSAppointment of Nominated Adviser & TVR
18th Dec 20257:00 amRNS-RAvacta reports new AVA6103 pharmacology data
17th Dec 20257:00 amRNSFaridoxorubicin Phase 1b SGC data
8th Dec 20257:00 amRNSPreliminary Data in Faridoxorubicin Phase 1b Trial
3rd Nov 20258:24 amRNSCompletion of Placing and TVR
27th Oct 20255:39 pmRNSBlock Listing Six Monthly Return
27th Oct 20257:00 amRNSAvacta presents preclinical data at AACR-NCI-EORTC
23rd Oct 20255:00 pmRNS-RNotice of Investor Presentation
20th Oct 20257:01 amRNSEquity fundraise of £16 million
20th Oct 20257:00 amRNSAvacta Presents Phase 1a Data for Faridoxorubicin
13th Oct 20257:00 amRNSAvacta to present data at EORTC-NCI-AACR
30th Sep 20257:00 amRNSInterim Half Year Results 2025
15th Sep 20257:00 amRNSNotice of Interim Results
9th Sep 20257:00 amRNS-RShortlisted for AIM Awards Technology of the Year
1st Sep 20257:00 amRNSAvacta completes sale of Coris Bioconcept
29th Aug 20257:00 amRNSAmendments to Convertible Bond + equity fundraise
30th Jul 20257:00 amRNSAvacta to Present at ESMO Congress
28th Jul 20257:48 amRNSAgreement to Sell Coris Bioconcept SRL
21st Jul 20257:00 amRNSPayment of Convertible Bond Installment
17th Jul 20257:00 amRNSEquity fundraise of £3.25 million
2nd Jul 20255:00 pmRNSResult of AGM
2nd Jul 20257:00 amRNSQ2 2025 Business Update
1st Jul 20257:00 amRNSManagement Team Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.